A possible strategy to improve the outcome for postmenopausal breast cancer patients is to design compounds with dual aromatase and tubulin targeting activities, which may offer the potential benefits of improved efficacy and fewer side effects [7,8]. Here, CYP19A1 is linked to breast carcinoma.